Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 6/20 | 0.94 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | TOP1 | P11387 | 3/20 | 0.44 |
| ▸ | CYCS | P99999 | 2/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.41 |
| ▸ | STAT1 | P42224 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL20240644 | 0.83 | TERT (0.67) | TERTENPP2TOP1CYCSSTAT3 | |
| Iodide SCHEMBL30767160 | 0.83 | TERT (0.67) | TERTENPP2TOP1CYCSSTAT3 | |
| SCHEMBL3465842 | 0.82 | TERT (0.65) | TERTENPP2TOP1CYCSSTAT3 | |
| SCHEMBL20380004 | 0.81 | TERT (0.85) | TERTENPP2TOP1CYCSSTAT3 | |
| SCHEMBL20380012 | 0.81 | TERT (0.85) | TERTENPP2TOP1CYCSSTAT3 | |
| SCHEMBL20379925 | 0.81 | TERT (0.85) | TERTENPP2TOP1CYCSSTAT3 | |
| Tmpyp4 SCHEMBL265519 | 0.80 | TERT (0.97) | TERTENPP2TOP1CYCS | |
| Tmpyp4 SCHEMBL29369473 | 0.79 | TERT (1.00) | TERTENPP2TOP1CYCS | |
| Tmpyp4 SCHEMBL20380171 | 0.79 | TERT (0.93) | TERTENPP2TOP1CYCS | |
| SCHEMBL30136 | 0.76 | TOP1 (0.64) | TERTENPP2TOP1CYCSSTAT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140243294-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | DUKE UNIVERSITY (US) | 2014-08-28 | — | — | US | disclosed |
| US-8759324-B2 | Method of activation of oxazaphosphorines | DUKE UNIVERSITY (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130172296-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | UNIV DUKE (US) | 2013-07-04 | — | — | US | disclosed |
| US-8399434-B2 | Method of activation of oxazaphosphorines | DUKE UNIVERSITY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20120077782-A9 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | DUKE UNIVERSITY (US) | 2012-03-29 | — | — | US | disclosed |
| US-20090318388-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | DUKE UNIVERSITY (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2008073195-A2 | METHOD FOR ACTIVATION OF OXAZAPHOSPHORINES | DUKE UNIVERSITY (US) | 2008-06-19 | — | — | WO | disclosed |
| US-20080113956-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2008-05-15 | — | — | US | disclosed |
| US-20070179124-A1 | Substituted Porphyrins | FRIDOVICH IRWIN | 2007-08-02 | — | — | US | disclosed |
| US-20060074062-A1 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2006-04-06 | — | — | US | disclosed |
| US-6916799-B2 | Substituted porphyrins | DUKE UNIVERSITY (US) | 2005-07-12 | — | — | US | disclosed |
| EP-1045851-B1 | SUBSTITUTED PORPHYRINS | UNIV DUKE (US) | 2003-04-23 | — | — | EP | disclosed |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | DUKE UNIVERSITY | 2002-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113956-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885ENPP2 399/4885TOP1 4291/4885 |
| US-20070179124-A1 | Substituted Porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885ENPP2 399/4885TOP1 4291/4885 |
| US-20090318388-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | PPOX, HMBS, OAT | TERT 3295/4885ENPP2 398/4885TOP1 1564/4885 |
| US-20020042407-A1 | Antiinflammatory agents; respiratory system disorders | LPO, PRDX5, MPO | TERT 3237/4885ENPP2 126/4885TOP1 4338/4885 |
| US-20060074062-A1 | Substituted porphyrins | PPOX, GPX4, PRDX5 | TERT 821/4885ENPP2 399/4885TOP1 4291/4885 |
| US-20140243294-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | PPOX, HMBS, OAT | TERT 3295/4885ENPP2 398/4885TOP1 1564/4885 |
| US-20120077782-A9 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | PPOX, HMBS, OAT | TERT 3295/4885ENPP2 398/4885TOP1 1564/4885 |
| US-20130172296-A1 | METHOD OF ACTIVATION OF OXAZAPHOSPHORINES | PPOX, HMBS, OAT | TERT 3295/4885ENPP2 398/4885TOP1 1564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.